Skip to main content
Top
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies

Authors: Liang Du, Yuqi Liu, Pei Xue, Chenxi Song, Jiani Shen, Qing He, Yuanling Peng, Xiang Tong, Lizhi Tang, Yonggang Zhang

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

The associations between the Arg399Gln polymorphism in X-ray repair cross-complementing gene 1 (XRCC1) gene and the risk of hematological malignancies have been extensively investigated. However, the results were inconsistent. The objective of the current study is to investigate the association by meta-analysis. We searched PubMed database, Embase database, CNKI database, Wanfang database, and Weipu database, covering all studies until August 7, 2013. Statistical analysis was performed by using the Revman4.2 software and the Stata10.0 software. A total of 27 case–control studies concerning the Arg399Gln polymorphism were included from 26 articles. The results suggested that the Arg399Gln polymorphism was not associated with an increased/decreased risk of hematological malignancies in total analysis (OR = 1.15, 95 % confidence interval (CI) = 0.97–1.35, P = 0.10 for Arg/Gln + Gln/Gln vs. Arg/Arg). In the subgroup analysis by ethnicity and cancer types, significant association was found in Asians (OR = 1.35, 95 % CI = 1.04–1.75, P = 0.03) but not in Europeans (OR = 1.07, 95 % CI = 0.86–1.33, P = 0.56), and in leukemia (OR = 1.25, 95 % CI = 1.02–1.54, P = 0.03) but not in lymphoma (OR = 0.98, 95 % CI = 0.80–1.20, P = 0.84) or myeloma (OR = 1.13, 95 % CI = 0.23–5.69, P = 0.88). The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia. In future, more large-scale case–control studies are needed to validate these results.
Literature
1.
go back to reference Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dolken G, Klenner A, Hanel M, Herbst R, Junghanss C, Ehninger G, Study Alliance L. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–16. doi:10.1016/S0140-6736(12)60689-8.CrossRef Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dolken G, Klenner A, Hanel M, Herbst R, Junghanss C, Ehninger G, Study Alliance L. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–16. doi:10.​1016/​S0140-6736(12)60689-8.CrossRef
2.
go back to reference Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA : the journal of the American Medical Association. 2011;306(17):1874–83. doi:10.1001/jama.2011.1558.CrossRefPubMed Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA : the journal of the American Medical Association. 2011;306(17):1874–83. doi:10.​1001/​jama.​2011.​1558.CrossRefPubMed
5.
go back to reference Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011;61(4):212–36. doi:10.3322/caac.20121. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a cancer journal for clinicians. 2011;61(4):212–36. doi:10.​3322/​caac.​20121.
6.
go back to reference Abramenko I, Bilous N, Chumak A, Kostin A, Martina Z, Dyagil I. DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl nuclear power plant accident. J Radiat Res. 2012;53(3):497–503.CrossRefPubMed Abramenko I, Bilous N, Chumak A, Kostin A, Martina Z, Dyagil I. DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of Chernobyl nuclear power plant accident. J Radiat Res. 2012;53(3):497–503.CrossRefPubMed
12.
go back to reference Canalle R, Silveira VS, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52(6):1118–26. doi:10.3109/10428194.2011.559672.CrossRefPubMed Canalle R, Silveira VS, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. Impact of thymidylate synthase promoter and DNA repair gene polymorphisms on susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52(6):1118–26. doi:10.​3109/​10428194.​2011.​559672.CrossRefPubMed
16.
17.
go back to reference Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genetics and molecular research : GMR. 2009;8(4):1451–8. doi:10.4238/vol8-4gmr687.CrossRefPubMed Meza-Espinoza JP, Peralta-Leal V, Gutierrez-Angulo M, Macias-Gomez N, Ayala-Madrigal ML, Barros-Nunez P, et al. XRCC1 polymorphisms and haplotypes in Mexican patients with acute lymphoblastic leukemia. Genetics and molecular research : GMR. 2009;8(4):1451–8. doi:10.​4238/​vol8-4gmr687.CrossRefPubMed
19.
go back to reference Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(2):258–65. doi:10.1158/1055-9965.EPI-05-0583.CrossRef Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schollkopf C, Chang ET, et al. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(2):258–65. doi:10.​1158/​1055-9965.​EPI-05-0583.CrossRef
20.
go back to reference Stanczyk M, Sliwinski T, Cuchra M, Zubowska M, Bielecka-Kowalska A, Kowalski M, et al. The association of polymorphisms in DNA base excision repair genes XRCC1, OGG1 and MUTYH with the risk of childhood acute lymphoblastic leukemia. Mol Biol Rep. 2011;38(1):445–51. doi:10.1007/s11033-010-0127-x.CrossRefPubMed Stanczyk M, Sliwinski T, Cuchra M, Zubowska M, Bielecka-Kowalska A, Kowalski M, et al. The association of polymorphisms in DNA base excision repair genes XRCC1, OGG1 and MUTYH with the risk of childhood acute lymphoblastic leukemia. Mol Biol Rep. 2011;38(1):445–51. doi:10.​1007/​s11033-010-0127-x.CrossRefPubMed
21.
go back to reference Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100(10):3761–6. doi:10.1182/blood-2002-04-1152.CrossRefPubMed Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100(10):3761–6. doi:10.​1182/​blood-2002-04-1152.CrossRefPubMed
22.
go back to reference Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinc E. DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res. 2010;34(10):1275–81. doi:10.1016/j.leukres.2010.02.035.CrossRefPubMed Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinc E. DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res. 2010;34(10):1275–81. doi:10.​1016/​j.​leukres.​2010.​02.​035.CrossRefPubMed
23.
go back to reference Matsuo K, Hamajima N, Suzuki R, Andoh M, Nakamura S, Seto M, et al. Lack of association between DNA base excision repair gene XRCC1 Gln399Arg polymorphism and risk of malignant lymphoma in Japan. Cancer Genet Cytogenet. 2004;149(1):77–80.CrossRefPubMed Matsuo K, Hamajima N, Suzuki R, Andoh M, Nakamura S, Seto M, et al. Lack of association between DNA base excision repair gene XRCC1 Gln399Arg polymorphism and risk of malignant lymphoma in Japan. Cancer Genet Cytogenet. 2004;149(1):77–80.CrossRefPubMed
24.
go back to reference Xia MJ, Shan J, Li YP, Zhou YN, Guo YJ, Sun GX, et al. Adoptive transfusion of tolerogenic dendritic cells prolongs the survival of liver allograft: a systematic review. J Evid Based Med. 2014;7(2):135–46. Xia MJ, Shan J, Li YP, Zhou YN, Guo YJ, Sun GX, et al. Adoptive transfusion of tolerogenic dendritic cells prolongs the survival of liver allograft: a systematic review. J Evid Based Med. 2014;7(2):135–46.
25.
go back to reference Zhang L, Chen LM, Wang MN, Chen XJ, Li N, De HY, et al. The G894t, T-786c and 4b/a polymorphisms in Enos gene and cancer risk: a meta-analysis. J Evid Based Med. 2014;7(4):263–9. Zhang L, Chen LM, Wang MN, Chen XJ, Li N, De HY, et al. The G894t, T-786c and 4b/a polymorphisms in Enos gene and cancer risk: a meta-analysis. J Evid Based Med. 2014;7(4):263–9.
27.
go back to reference Deligezer U, Akisik EE, Dalay N. Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia. Anticancer Res. 2007;27(4B):2453–6.PubMed Deligezer U, Akisik EE, Dalay N. Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia. Anticancer Res. 2007;27(4B):2453–6.PubMed
28.
go back to reference Duman N, Aktan M, Ozturk S, Palanduz S, Cakiris A, Ustek D, et al. Investigation of Arg399Gln and Arg194Trp polymorphisms of the XRCC1 (X-ray cross-complementing group 1) gene and its correlation to sister chromatid exchange frequency in patients with chronic lymphocytic leukemia. Genetic testing and molecular biomarkers. 2012;16(4):287–91. doi:10.1089/gtmb.2011.0152.CrossRefPubMed Duman N, Aktan M, Ozturk S, Palanduz S, Cakiris A, Ustek D, et al. Investigation of Arg399Gln and Arg194Trp polymorphisms of the XRCC1 (X-ray cross-complementing group 1) gene and its correlation to sister chromatid exchange frequency in patients with chronic lymphocytic leukemia. Genetic testing and molecular biomarkers. 2012;16(4):287–91. doi:10.​1089/​gtmb.​2011.​0152.CrossRefPubMed
29.
go back to reference Ganster C, Neesen J, Zehetmayer S, Jager U, Esterbauer H, Mannhalter C, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Gene Chromosome Cancer. 2009;48(9):760–7. doi:10.1002/gcc.20680.CrossRef Ganster C, Neesen J, Zehetmayer S, Jager U, Esterbauer H, Mannhalter C, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Gene Chromosome Cancer. 2009;48(9):760–7. doi:10.​1002/​gcc.​20680.CrossRef
32.
go back to reference Li J (2011) Association of XRCC1 polymorphis with leukemia susceptibility in northwest Chinese population. Li J (2011) Association of XRCC1 polymorphis with leukemia susceptibility in northwest Chinese population.
34.
go back to reference Özcan A, Pehlivan M, Tomatir AG, Karaca E, Oezkinay C, Özdemir F, et al. Polymorphisms of the DNA repair gene XPD (751) and XRCC 1(399) correlates with risk of hematological malignancies in Turkish population. Afr J Biotechnol. 2011;10(44):8860–70.CrossRef Özcan A, Pehlivan M, Tomatir AG, Karaca E, Oezkinay C, Özdemir F, et al. Polymorphisms of the DNA repair gene XPD (751) and XRCC 1(399) correlates with risk of hematological malignancies in Turkish population. Afr J Biotechnol. 2011;10(44):8860–70.CrossRef
35.
go back to reference Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48(1):16–20. doi:10.1002/pbc.20742.CrossRefPubMed Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48(1):16–20. doi:10.​1002/​pbc.​20742.CrossRefPubMed
36.
go back to reference Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM. Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians. Haematologica. 2008;93(10):1597–600. doi:10.3324/haematol.13159.CrossRefPubMed Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM. Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians. Haematologica. 2008;93(10):1597–600. doi:10.​3324/​haematol.​13159.CrossRefPubMed
37.
go back to reference Shi JY, Ren ZH, Jiao B, Xiao R, Yun HY, Chen B, et al. Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. International journal of cancer Journal international du cancer. 2011;128(1):233–8. doi:10.1002/ijc.25318.CrossRefPubMed Shi JY, Ren ZH, Jiao B, Xiao R, Yun HY, Chen B, et al. Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. International journal of cancer Journal international du cancer. 2011;128(1):233–8. doi:10.​1002/​ijc.​25318.CrossRefPubMed
38.
go back to reference Zhang J (2003) Relationship between environmental risk factors, genetic polymorphisms and adult acult leukemia. Zhang J (2003) Relationship between environmental risk factors, genetic polymorphisms and adult acult leukemia.
39.
go back to reference Zhu R, Wu Y, Lu FJ, Wang AH, Tang JY, Zhao JC, et al. Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: a case–control analysis. Eur J Oncol. 2008;13(3):187–92. Zhu R, Wu Y, Lu FJ, Wang AH, Tang JY, Zhao JC, et al. Polymorphisms and haplotypes of XRCC1 and APE1 and risk of childhood leukaemia in China: a case–control analysis. Eur J Oncol. 2008;13(3):187–92.
41.
go back to reference Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for pre-clinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015. doi:10.1111/jebm.12141. Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for pre-clinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015. doi:10.​1111/​jebm.​12141.
Metadata
Title
The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies
Authors
Liang Du
Yuqi Liu
Pei Xue
Chenxi Song
Jiani Shen
Qing He
Yuanling Peng
Xiang Tong
Lizhi Tang
Yonggang Zhang
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3099-6

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine